Corxel
- Health & Biotech
- Berkeley Heights, NJ, US
- Founded 2019
- Private
- corxelbio.com
Clinical-stage biopharma developing cardiometabolic drugs, led by CX11, an oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes.
$287MEquity raised in 2025–20262025 — · 2026 $287M · 1 equity round
$287MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 1 round · 2 sources
Earlier rounds not yet sourced. Corxel was founded in 2019 and raised before 22 Jan 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.
- Series D1Amount$287MPost-money—✓ Confirmed
- Earlier rounds not yet sourced
Investors 10
- Adage Capital Management
- HBM Healthcare Investments
- Hengdian Group Capital
- Invus
- RA Capital Management
- RTW Investments
- SilverArc Capital
- SR One
- SymBiosis
- TCG Crossover
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
Parabilis MedicinesHealth · $975M in 2025–2026Shared: RA Capital Management, SymBiosis +1Dren BioHealth · $350M in 2025–2026Shared: SR One, HBM Healthcare InvestmentsEncoded TherapeuticsHealth · $275M in 2025–2026Shared: Invus, RTW InvestmentsPsiQuantumDeep Tech · $1B in 2025–2026Shared: Adage Capital ManagementKailera TherapeuticsHealth · $600M in 2025–2026Shared: Adage Capital ManagementOllin BiosciencesHealth · $430M in 2025–2026Shared: RA Capital Management
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Corxel and its logo are trademarks of their owners, used here for identification only.
